
The modern platform for creating, sharing, and collaborating on AI prompts. Advanced version control and real-time testing.

Trials.ai
NxtCure
Patient first Clinical Intelligence platform.

Website, pricing, platforms and company facts side by side.
|
|
|
|
|---|---|---|
| Website | diffyn.com | hekma.ai |
| Pricing | — | |
| Platforms | — | |
| Company | — | Startup from the United States · 50 - 99 employees |
| Listed in |
In their own words, as submitted to SaaSHub.


No description of Diffyn yet.
HEKMA is an AI-powered clinical trial intelligence company focused on accelerating clinical research by improving patient recruitment, trial feasibility, and patient engagement. The company serves CROs, pharmaceutical sponsors, hospitals, and patients through an integrated platform that connects...
What each product offers, as listed by its team.


An editorial look at what each product does well and who it suits.


Overall verdict
Why this product is good
Recommended for
No analysis of HEKMA yet.
Walkthroughs and reviews on video.
The Ultimate Prompt Tool for Creators – Visualize & Organize with Diffyn
No HEKMA videos yet. You could help us improve this page by suggesting one.
How often each product is chosen within a category, 0–100% relative to the other.


As answered by people managing Diffyn and HEKMA.
Diffyn's answer
Addresses workflow and change management on LLM prompts, provide teams with traceability and visualization of tests across multiple models, provide deeper understading into efficiency of these prompts.
HEKMA's answer:
HEKMA is a patient-centric AI platform built by doctors, AI specialists, and enterprise solution architects, connecting underrepresented populations to clinical trials and generating new revenue streams for clinics and hospitals. Its differentiator is running both directions at once: matching a patient's profile against every eligible trial while also making that patient discoverable to study teams searching for participants like them. It also stays engaged post-enrollment with a live study feed that gives phase-by-phase transparency and plain-English updates from the study team, addressing the gap where most trial participants never learn their study's outcome.
Diffyn's answer
Diffyn is the platform that specializes on both change management and multi-model analysis.
HEKMA's answer:
Most trial-matching tools stop at "here's a list of trials." HEKMA's edge is the full lifecycle: an AI-organized health record pulled from connected EHRs, weekly AI trial matching in plain English, an appointment hub, medication adherence tracking shared with study teams only by consent, and connected wearable/device data stored as FHIR R4 observations. For hospitals and sponsors specifically, the pitch is unlocking diverse, underrepresented patient populations and turning innovation labs into commercial profit centers, addressing well-documented enrollment gaps.
Diffyn's answer
React, Next.js, POSTGRESQL
HEKMA's answer:
Machine-driven intelligence built from EHR and patient-generated data, standardized to FHIR R4 observations, with integrations across Apple Watch, Apple Health, Google Health Connect and more . Compliance/security stack: HIPAA, GDPR, SOC 2 Type II, ISO 27001, UAE PDPL, 21 CFR Part 11, and ICH GCP E6(R3).
Diffyn's answer
Professionals incorporating LLMs or AI tools in their workflow and wants to keep track of changes and test their prompts.
HEKMA's answer:
Three segments, per HEKMA's own site structure: (1) patients with serious/chronic/rare conditions seeking trials, (2) trial sponsors and CROs seeking diverse recruitment, and (3) patient advocacy groups (PAGs), given a dedicated workspace to manage and engage their communities, plus hospitals/sponsors directly (the platform serves patients, PAGs, sponsors, CROs, and research sites).
Diffyn's answer
I started working on Diffyn when I notice that prompting has become an essential part of work across many industries. While there are version control platofrms like github, they are not designed for just prompt management are can be overkill such applications, it is also not integrated natively with various LLMs and relevant tools for users to validate ideas and visualise results properly.
HEKMA's answer:
HEKMA was born from a simple, painful observation: patients and caregivers searching for the next option, often a clinical trial, when standard treatment runs out, lose critical time not to the disease itself, but to a broken system. Families spend months piecing together eligibility criteria, chasing down trial coordinators, and hoping to find the right study before it's too late. HEKMA's founders set out to compress that search from years to days, building an AI-driven platform that meets patients and caregivers where they are and connects them to life-changing research faster than the traditional referral pathway ever could.
HEKMA's answer:
We just have Rocket Trials as the biggest customer now!
Share your experience with using Diffyn and HEKMA. For example, how are they different and which one is better?